Glenmark Pharmaceuticals has reported results for second quarter ended September 30, 2023 (Q2FY24).
The company has reported 28.55% fall in its net profit at Rs 302.35 crore for the quarter under review as compared to Rs 423.15 crore for the same quarter in the previous year. Total income of the company decreased by 8.63% at Rs 2,306.99 crore for Q2FY24 as compared to Rs 2,524.94 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported net loss after tax for the period continuing and discontinuing operations at Rs 61.56 crore for Q2FY24 as compared to net profit of Rs 278.67 crore for the same quarter in the previous year. However, total income of the company increased by 3.38% at Rs 3,209.07 crore for Q2FY24 as compared to Rs 3,104.29 crore for the corresponding quarter previous year.
